Thyrocare Technologies Limited has filed its quarterly compliance certificate with the National Stock Exchange and BSE for the quarter ended March 31, 2026, pursuant to Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018.

Regulatory Compliance Filing

The certificate was submitted on April 06, 2026, by Company Secretary and Compliance Officer Brijesh Kumar to both major stock exchanges. The filing addresses the mandatory requirements under SEBI regulations for depositories and participants.

Certificate Confirmation

MUFG Intime India Private Limited (formerly Link Intime India Private Limited), serving as the company's Registrar and Share Transfer Agent, issued the certificate confirming compliance status. The registrar confirmed that:

• The entire holding of Thyrocare Technologies' shares remains in dematerialized form
• No requests for rematerialisation were received from any company members during Q4FY26
• Regulation 74(5) is not applicable to the company due to complete dematerialization

Registrar Details

The certificate was issued by Ashok Shetty, Sr. Vice President-Corporate Registry at MUFG Intime India Private Limited. The registrar operates from its registered address in Vikhroli (West), Mumbai, and maintains the company's share transfer records.

This quarterly filing represents standard regulatory compliance for listed companies, ensuring transparency in share ownership and transfer processes as mandated by SEBI regulations.

Docon Technologies Private Limited has filed an updated disclosure under Regulation 31 of SEBI (SAST) Regulations, 2011, regarding the encumbrance on shares of Thyrocare Technologies Limited. The update follows a significant corporate action by API Holdings Limited involving the partial redemption of its Series 1 Non-Convertible Debentures.

Partial Redemption Details

API Holdings Limited executed a partial redemption of its Series 1 Non-Convertible Debentures aggregating to INR 1,200 million on March 30, 2026. The redemption was structured through a reduction in face value per debenture from INR 10,00,000 to INR 9,00,000.

Share Encumbrance Status

Despite the partial redemption, there has been no change in the number of encumbered shares of Thyrocare Technologies Limited held by Docon Technologies Private Limited. The encumbrance details remain as follows:

Updated Debenture Structure

Following the partial redemption, the Series 1 Debentures now comprise 12,000 unlisted, unrated, secured, redeemable, non-convertible debentures with a reduced face value of INR 9,00,000 per debenture, aggregating to a nominal value of INR 10,800 million.

Major Debenture Holders

The disclosure reveals the current composition of debenture holders following the redemption:

Regulatory Compliance

The updated disclosure was made to both the National Stock Exchange of India Limited and BSE Limited, along with Thyrocare Technologies Limited, in compliance with Regulation 31 of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011. This follows previous disclosures made on September 24, 2025, November 11, 2025, and December 05, 2025.

The encumbrance on Docon's shares was created pursuant to a corporate guarantee extended by Docon Technologies Private Limited to secure the obligations of API Holdings Limited, its holding company, in respect of facilities availed through the issuance of the non-convertible debentures.